{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:19:00Z","timestamp":1789399140754,"version":"build-2803163510"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.euo.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T21:51:04Z","timestamp":1719697864000},"page":"971-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity"],"prefix":"10.1016","volume":"7","author":[{"given":"Lisa M.","family":"Cordes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.06.001_b0005","series-title":"Xtandi (enzalutamide) package insert","author":"Pharma","year":"2023"},{"key":"10.1016\/j.euo.2024.06.001_b0010","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.06.001_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2024.06.001_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"issue":"4 Suppl","key":"10.1016\/j.euo.2024.06.001_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2024.42.4_suppl.15","article-title":"Outcomes of men with high-risk biochemically recurrent prostate cancer who suspend enzalutamide monotherapy treatment in the phase 3 EMBARK study","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T23:17:43Z","timestamp":1727219863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2588931124001482"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}